XCancer

Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors

Description:

Urokinase plasminogen activator receptor (uPAR), the cell-surface receptor for its ligand uPA, plays a critical role in regulating cell migration and invasion-key drivers of cancer progression. This study aims to evaluate a novel uPAR-targeting radiopharmaceutical pair: the diagnostic agent \[⁶⁸Ga\]Ga-HT547 and the therapeutic agent \[¹⁷⁷Lu\]Lu-HT547. In patients with breast cancer, head and neck cancer, pancreatic cancer, or glioma, we will assess the diagnostic performance and biodistribution of these tracers using \[⁶⁸Ga\]Ga-HT547 and \[¹⁷⁷Lu\]Lu-HT547 SPECT/CT.

Sponsor:

First Affiliated Hospital of Chongqing Medical University

Phase:

Early Phase 1

Contacts:

Hua Pang, Doctor (CONTACT)

phua1973@163.com

+8615923039337

Government Study Link:

NCT07639970 - Click here to see study on

ClinicalTrials.gov

HT547

Isotope(s):
Target(s):
  • uPAR

HT547

Isotope(s):
Target(s):
  • uPAR
Inclusion
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • 1. Willing and able to communicate with the investigator, understand and comply with trial requirements, voluntarily participate in the trial, and provide written informed consent.
  • Patients with solid tumors (breast cancer, head and neck cancer, pancreatic cancer, or brain glioma) confirmed by histology or cytology.
  • Expected survival of at least 3 months.
  • Aged 18 years or older, regardless of gender.
Exclusion
  • Received any investigational drug within 28 days prior to the first dose, or concurrent participation in another clinical study (except: participation in an observational, non-interventional study, or being in the follow-up phase of an interventional study).
  • Received immunotherapy, chemotherapy, radiotherapy, or other anti-tumor therapy within 4 weeks prior to the first dose.
  • 1. Pregnant or breastfeeding women, or women with a positive baseline pregnancy test.
  • Received blood transfusion within 4 weeks prior to screening to meet the enrollment criteria.
  • History of severe allergic reaction to any component of the investigational drug injection.